Anavex Life Sciences has recently announced promising results from a Phase 2b/3 clinical trial
evaluating blarcamesine, an investigational drug for early Alzheimer’s disease.
The study revealed significant reductions in pathological amyloid-ß levels and
a marked slowdown in brain atrophy among patients treated with the drug.
The trial involved 508 participants from multiple medical centers across five countries.
Participants were randomly assigned to receive either blarcamesine or a
placebo. Over 48 weeks, the efficacy of the drug was assessed using the
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and Alzheimer’s
Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales.
Blarcamesine, developed by Anavex, demonstrated substantial improvements in cognitive function. Patients treated with
the drug showed a significant increase in plasma Aβ42/40 ratios, indicating its
effective anti-amyloid properties. MRI scans also revealed a notable reduction
in brain volume loss compared to the placebo group.
Dr. Marwan Noel Sabbagh, professor of neurology, emphasized the potential impact of these
findings. “There is hope that new therapies for Alzheimer that target the
disease beyond amyloid may slow progression for many with the earliest forms of
the disease,” he stated. Blarcamesine offers the advantage of being a
small, oral molecule that can exert clinical benefits on cognition and
neurodegeneration.
Safety profiles for blarcamesine were also encouraging. The most common adverse event reported was
dizziness, which was generally mild to moderate and transient in nature. Anavex Life Sciences remains committed to advancing blarcamesine as a potential treatment
option for Alzheimer’s disease, aiming to provide a convenient, orally
available therapy for patients.
Christopher U Missling, PhD, president and CEO of Anavex, expressed gratitude to all involved
in the study. “We look forward to continuing our efforts in developing
blarcamesine as a viable treatment for Alzheimer’s disease,” he said.
Refer to this article to learn more.
More about Anavex on https://www.bloomberg.com/profile/company/AVXL:US